DEA Telehealth Extension Tracker: Prescribing Into 2027

The DEA extended its telehealth flexibilities a fourth time on December 30, 2025, keeping them in effect through December 31, 2026. Through that date, a DEA-registered prescriber can issue Schedule II-V controlled substances by telehealth without ever examining the patient in person, stimulants included. The permanent replacement rule is still unfinished, so this page runs as a living tracker: current status, the full extension history, the proposed special-registration framework, and a checklist to work through before the deadline. We update it when the rules move.

This is practice-operations guidance for planning purposes and is not legal or clinical advice. Controlled-substance prescribing carries real liability, and the rules below interact with your state law and your malpractice policy. Confirm anything load-bearing with your own attorney and carrier before you rely on it.

Where do the DEA telehealth rules stand right now?

Every row below is current as of August 17, 2026, and we edit this table whenever a row changes.

Can you prescribe controlled substances by telehealth right now?

Yes, through December 31, 2026. A DEA-registered prescriber can issue Schedule II-V controlled medications over a two-way audio-video telemedicine visit without a prior in-person evaluation, as long as the prescription follows DEA rules, your state's rules, and the ordinary standard of care. DEA and HHS framed the fourth extension as a bridge while they finish the permanent telemedicine rule.

The workflow most telepsychiatry practices have run since 2020 is still legal. You can take a new ADHD patient entirely by video, confirm the diagnosis, check the prescription drug monitoring program, and send a stimulant to their pharmacy. You do not need to have met them in a physical room first.

Two things are still true underneath the flexibility. You need a valid DEA registration, which is one of the non-negotiable line items when you open the doors. And the patient's own state can be stricter than the federal rule, which we cover below. The flexibility removes the federal in-person requirement and leaves every other requirement standing.

Changelog: every extension so far

Four temporary extensions have kept the COVID-era flexibility alive since 2023, and the table below is the entire history. It doubles as your base rate for guessing what happens next.

Read the timing column carefully before you build a plan around it. Extensions have arrived anywhere from weeks ahead of the operative deadline to the day before: the first came in May 2023, the second in October 2023, the third in November 2024, and the fourth surfaced on December 30, 2025, with the flexibility due to lapse two days later. Assume you will get no advance notice and you will never be caught out.

This page's own history: first published June 30, 2026; rewritten as a living tracker with the special-registration explainer and the year-end checklist on August 17, 2026.

What is the special-registration rule that would replace all this?

It is the DEA's proposed permanent framework, published January 17, 2025, and it would swap the blanket flexibility for a system of new telemedicine registrations layered on top of your existing DEA registration. The proposal has three tiers:

• Telemedicine Prescribing Registration. For qualified clinician practitioners generally; authorizes Schedule III-V prescribing by telemedicine.
• Advanced Telemedicine Prescribing Registration. For specialized practitioners, with psychiatrists named explicitly; authorizes Schedule II-V. This is the tier a telepsychiatry practice would live in, because stimulants sit in Schedule II.
• Telemedicine Platform Registration. For covered online telemedicine platforms that dispense controlled substances, aimed at large direct-to-consumer operations rather than a solo practice.

On top of the tier itself, the proposal adds a State Telemedicine Registration for every state where a patient is located during treatment, PDMP checks before prescribing, identity-verification steps, and data reporting to the DEA. The comment period closed March 18, 2025 after drawing tens of thousands of comments, many arguing the guardrails were heavier than small practices could carry.

As of August 2026 there is no final rule. The agencies have described the fourth extension as time to finish the permanent framework, and trade groups expect final action before the current deadline. Expect is the operative word: no final rule has been scheduled, and proposals routinely change between comment period and finalization. Plan against the proposal's general shape, and hold the details loosely.

What happens if the flexibility lapses? Ryan Haight is the default

If the flexibility ends with nothing in its place, the country reverts to the Ryan Haight Act. Passed in 2008 after deaths tied to online no-exam pharmacies, it requires at least one in-person medical evaluation before a practitioner prescribes a controlled substance, with a short list of narrow exceptions. Under that default, a video-only first visit stops being a lawful basis for a controlled-substance prescription.

The exception worth memorizing is the in-person-exam pathway, because it survives no matter what the DEA does next. A patient who has had one qualifying in-person evaluation can be prescribed controlled substances by telehealth afterward. The exam can be one you performed yourself or, under the statute's referral exception, one performed by another DEA-registered practitioner who then refers the patient to you. For a telepsychiatry practice that creates two durable fallbacks: keep access to a physical space, even a borrowed exam room a few days a month, so the one qualifying visit is always available; or, for an established patient, arrange for their primary care physician to write the prescription on your recommendation while you continue the diagnostic and management relationship. The contours of these exceptions are technical, and a health-law attorney should confirm them for your situation. The planning point is simpler: everything durable runs through the in-person evaluation.

Will there be a fifth extension?

Nobody knows, and every honest answer starts there. What the record supports: four deadlines have come and gone, and each ended in an extension rather than a lapse. A reversion would disrupt care overnight for millions of patients across psychiatry, addiction medicine, and pain management, and no agency has shown an appetite for that. One physician who oversees a large multi-provider telehealth group relayed that a DEA official, speaking publicly during an earlier cycle, called another short extension the most realistic outcome for exactly that reason.

Treat the pattern as a planning input rather than a promise. Run your practice normally, keep the checklist below current, and let December 31 stay real on your calendar until the Federal Register says otherwise.

Can you still prescribe Adderall by telehealth in 2027?

Through December 31, 2026, yes. For January 1, 2027 onward, the honest answer is that the rule has not been written yet. Three outcomes are on the table: a finalized special-registration framework, under which psychiatrists would sit in the Advanced tier that covers Schedule II stimulants; a fifth temporary extension, which keeps today's rules; or a lapse back to the Ryan Haight default, which would require an in-person evaluation before new telehealth stimulant prescriptions. Two of the three preserve a telehealth pathway for ADHD care. Prepare for the third anyway, and if your panel is ADHD-heavy, take the checklist below most seriously of anyone, because Schedule II medications face the tightest rules under every scenario.

What to do before December 31, 2026

Six items, all cheap to do now and expensive to improvise in late December.

1. Build the exposure list. Pull every patient you prescribe controlled substances to and flag the ones who have never had a qualifying in-person evaluation, with you or via referral. Those are the patients whose care changes if the flexibility lapses. Sort by schedule, since Schedule II patients face the tightest rules under every scenario. Juan Rodriguez, MD, who reviewed this guide, puts it plainly: "Build the list of controlled-substance patients you have never examined in person while it is still an afternoon project. If the rule changes, that list is your December."
2. Get PDMP access for every state where you have patients. Every version of 2027 leans on PDMP checks: the proposed special registration requires them, the buprenorphine rule requires them, and many states already do. Approval can take days to weeks per state, so register ahead of need. If your patients move or travel, the guide to seeing telehealth patients across state lines covers keeping their location current, which is also what determines whose PDMP you check.
3. Sketch your registration scenario. If the proposal finalizes near its current shape, a telepsychiatry practice would need the Advanced tier plus a State Telemedicine Registration for each patient state. Map that against where your DEA registrations sit today; the rules for whether you need a DEA registration in every state are their own maze, and knowing your current footprint is the first step of any application sprint.
4. Keep an in-person option warm. A sublet or borrowed exam room a few days a month keeps the Ryan Haight pathway open for every patient within driving distance. If you are fully remote and far from your panel, start building the referral relationships with local physicians now, before you need a favor on a deadline.
5. Put the policy on paper. Your controlled-substance policy should already say what happens on a rule change: how patients are notified, what the bridge plan is, and when prescribing stops. The controlled-substance policy template has language you can adapt.
6. Set two tripwires. Calendar a status check for October 1 and a decision point for November 15, 2026. If no extension or final rule has been published by November 15, decide deliberately between the wait-and-see posture and the contingency sequence below; six weeks is roughly the runway carriers say a clean termination-with-notice requires. The fourth extension surfaced on December 30, so silence in mid-December is normal under the observed pattern. The tripwire exists so you decide on a date you chose, under no time pressure, instead of reacting to news that may arrive at the last minute.

What to do if the flexibility actually expires

The cleanest contingency plan, the kind malpractice carriers circulate when a deadline approaches, is a short decision tree you can run per patient:

1. Identify who is exposed. This is the exposure list from the checklist above. Patients who have been seen in person, or who came to you by referral after an in-person exam elsewhere, are already covered. Telehealth-only controlled-substance patients are the ones at risk.
2. Offer an in-person visit. For exposed patients within reach of a physical location, schedule the one in-person evaluation that brings them back under the rules. This is the first choice whenever it is feasible.
3. If in-person is impossible, start termination with adequate notice. Patient abandonment is its own liability, so a proper notice period is mandatory. Carriers have advised starting the termination process on the order of six weeks ahead of a hard deadline, so there is time to give notice, bridge or transfer care, and provide referrals before prescribing has to stop.
4. A wait-and-see posture is defensible, with a tripwire. Given the four-extension pattern, some prescribers reasonably hold off on disrupting patients until a change is confirmed. If you take that approach, the November 15 decision point above is what keeps it defensible: you still have time to execute steps 2 and 3 if no extension comes.

On patient communication, the consensus from practices that have lived through several of these cycles is to avoid mass-alarming people prematurely. Answer questions as they arise, keep your own plan ready, and send a general notice only once a change is actually finalized. Frightening a stable panel over a deadline that has been extended four times does more harm than good.

Why your pharmacy refuses a legal telehealth script, and what to say

Pharmacies sometimes refuse to fill a controlled-substance prescription from a telehealth-only prescriber even when the prescription is fully legal. Large chains have turned away telepsychiatry stimulant and benzodiazepine scripts citing an in-person requirement that the federal flexibility had already waived. The refusal usually reflects an internal corporate policy or an overcautious reading rather than any legal prohibition on the fill.

When it happens, two moves usually resolve it:

• Ask the pharmacist to show you the specific policy they are citing. Often it is an internal chain policy rather than a legal requirement, and naming that distinction changes the conversation. The current DEA telemedicine documents are public; keeping the fourth-extension citation on hand is worth the few minutes it takes.
• Build pharmacy relationships before you need them. A practice with a few hundred patients can manage pharmacy friction through relationships in a way a faceless high-volume operation cannot. Knowing which local and mail-order pharmacies reliably fill your telehealth scripts, and routing patients accordingly, prevents most of these standoffs.

Some pharmacies also balk at out-of-state or out-of-area prescribers independent of any federal rule. That is a separate friction from the Ryan Haight question, and it points back to where your DEA registration and the patient sit, which we cover in the guide to multi-state licensing and the IMLC.

State law can be stricter than federal

The federal flexibility does not preempt your state. If a state requires an in-person visit before controlled-substance prescribing, that requirement controls even while the federal waiver is in effect. States set their own telehealth and controlled-substance rules, and they do not reliably mirror the federal framework. At least one state terminated its own controlled-substance telehealth waiver while the federal flexibility was still running, which stranded prescribers who had assumed the federal rule was the whole story.

So check both layers, every time you add a state. Your state medical or osteopathic board is the primary source, and most state medical associations track this actively. The Center for Connected Health Policy maintains a survey of telehealth prescribing rules across all states and is a good starting map. Document the patient's physical location at each telehealth visit, because the patient's location determines which state's rules apply, which PDMP you check, and, under the proposed permanent rule, which State Telemedicine Registrations you would need.

Where the software fits, and where it does not

Once a controlled-substance prescription is clinically appropriate and legal, sending it should be one step. Eureka's built-in e-prescribing includes EPCS for Schedule II-V controlled substances, so the act of transmitting the script lives inside the same system as the chart and the visit, instead of a bolted-on second tool. Where EPCS is an add-on it is a real line item: Osmind prices it at $49 per clinician per month, and most platforms charge something comparable. Getting EPCS stood up is one of the things to sequence early when you start a practice, because the identity-proofing step takes real lead time. Note too that your DEA registration and prescribing run under your individual Type 1 NPI rather than your practice's Type 2.

Knowing whether a given prescription is allowed, for this patient, in this state, on today's rules, is still your call. No EHR currently watches the DEA's extension clock for you or tracks which of your patients have had a qualifying in-person exam. Treat the tooling as the part that sends a script cleanly, and treat the rules above as the part you own.

Where this leaves you for 2026 and 2027

Through December 31, 2026, prescribe controlled substances by telehealth the way you have been, within your state's rules and the standard of care. Work the six-item checklist while it is cheap. Keep an in-person option available, because the in-person evaluation survives every version of 2027. And resist restructuring a working practice around a reversion that has never actually arrived across four deadline cycles. When the rule changes for real, this page changes with it.